Articles related to MEDICAL MEETINGS AND EVENTS

Streamlining Oncology Communication: A New Approach to Patient-Physician Messaging A recent study presented at the 2023 ASCO Annual Meeting has shed light on the significant workload that secure patient-physician portal messages place on oncologists, prompting a call for more efficient triaging systems. Key Points: “Secure messages are now a part of healthcare delivery that directly benefits our patient access to their providers, but this comes at the expense of increased workload for oncologists.” Brandon Anderson, MD, lead author of the study and an internal medicine resident at Kaiser Permanente’s San Francisco Medical Center in California

Neoadjuvant Chemotherapy and Upfront Surgery: A Comparative Study in Resectable Pancreatic Cancer In a recent study presented at the 2023 ASCO Annual Meeting, researchers found no significant survival benefit of neoadjuvant chemotherapy over upfront surgery in patients with resectable pancreatic cancer. Key Points: “Results of this trial do not support neoadjuvant FOLFIRINOX as standard of care in resectable pancreatic cancer.” Knut Jørgen Labori, MD, PhD, Oslo University Hospital, Norway

Roswell Park Comprehensive Cancer Center Shines at ASCO 2023 Roswell Park Comprehensive Cancer Center recently showcased a series of groundbreaking research studies at the American Society of Clinical Research (ASCO) 2023 meeting, highlighting their commitment to advancing cancer management and clinical trials. “This study has revealed differences in transcriptional metabolic profiles and other drivers of disease, as well as immune profiles, between younger and older CRC populations. This biology should be explored in the future, as new avenues for treatment in younger CRC populations.” Dr. Deepak Vadehra from the “Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients” study

Reframing Diagnostic Errors towards Diagnostic Excellence: The Five-step Strategy As diagnostic errors continue to pose a significant challenge in the healthcare sector, Dr. Hardeep Singh from the Baylor College of Medicine offers an innovative approach to not just reduce these errors, but to redefine and promote diagnostic excellence. By following a five-step strategy, both physicians and health organizations can enhance diagnostic procedures, ensuring higher accuracy, efficiency, and patient satisfaction. Here are the key highlights from Dr. Singh’s session at the Internal Medicine Meeting 2023:

Pfizer is lagging behind its peers with Ibrance, but the pharma giant is attempting to unveil the potential of CDK2 inhibitors to overcome CDK4/6 resistance. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer and Blueprint gave presentations on posters about their respective agents, and Incyte, Cyclacel, and a few private biotechs also had clinical trials going on. Although there are some positive signs, the research is still in its very early stages, and it is not apparent whether CDK2 inhibition is a workable monotherapy method.

Luspatercept demonstrated superiority over epoetin alfa in improving red blood cell (RBC) transfusion independence in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS) who have not previously received erythropoiesis-stimulating agents (ESAs). These findings are part of a study that was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting: